Oncology Institute (NASDAQ:STLN) Stock Sale Disclosed by Sen. Richard Blumenthal

Key Points

• Sen. Richard Blumenthal disclosed multiple sales of Oncology Institute stock between September 18 and 23, 2026, with individual transactions ranging from $1,001 to $50,000.
• Oncology Institute shares opened at $6.29 and were down 6.3%; the company reported a quarterly loss of $0.08 per share but revenue of $161.28 million, above the $152.80 million analyst consensus.
• Analysts maintain a generally positive outlook, with four Buy ratings and one Sell rating, an average “Moderate Buy” consensus, and a $9.00 average price target; institutional investors own 36.86% of the stock.

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. NASDAQ: STLN. In a filing disclosed on October 26th, the Senator disclosed that they had sold between $15,001 and $50,000 in Oncology Institute stock on September 18th.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Oncology Institute NASDAQ: STLN on 9/23/2026.
• Sold $15,001 - $50,000 in shares of Oncology Institute NASDAQ: STLN on 9/22/2026.
• Sold $1,001 - $15,000 in shares of Oncology Institute NASDAQ: STLN on 9/22/2026.
• Sold $1,001 - $15,000 in shares of Oncology Institute NASDAQ: STLN on 9/18/2026.

Oncology Institute Trading Down 6.3%

STLN opened at $6.29 on Tuesday. The stock has a 50-day moving average of $6.46. Oncology Institute, Inc. has a 1 year low of $2.32 and a 1 year high of $7.13. The stock has a market cap of $621.70 million, a price-to-earnings ratio of -20.97 and a beta of 0.39.

Oncology Institute (NASDAQ:STLN - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $161.28 million for the quarter, compared to the consensus estimate of $152.80 million. As a group, equities analysts anticipate that Oncology Institute, Inc. will post -0.21 EPS for the current fiscal year.

Institutional Trading of Oncology Institute

Several hedge funds and other institutional investors have recently bought and sold shares of STLN. BlackRock Inc. acquired a new stake in shares of Oncology Institute in the second quarter valued at about $25,787,000. State Street Corp purchased a new position in shares of Oncology Institute during the 2nd quarter worth $8,432,000. Renaissance Technologies LLC lifted its holdings in Oncology Institute by 25.1% in the first quarter. Renaissance Technologies LLC now owns 902,809 shares of the company's stock valued at $2,772,000 after acquiring an additional 180,909 shares during the last quarter. Manatuck Hill Partners LLC purchased a new position in Oncology Institute during the second quarter worth about $2,444,000. Finally, Walleye Capital LLC acquired a new position in Oncology Institute in the 2nd quarter valued at about $2,421,000. 36.86% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have commented on STLN. BTIG Research raised their price target on Oncology Institute from $8.00 to $9.00 and gave the company a "buy" rating in a report on Thursday, July 9th. Lake Street Capital initiated coverage on Oncology Institute in a research note on Monday, July 6th. They set a "buy" rating and a $10.00 price objective on the stock. Needham & Company LLC lifted their price target on shares of Oncology Institute from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, October 14th. Finally, Weiss Ratings assumed coverage on shares of Oncology Institute in a research note on Thursday, August 6th. They set a "sell (d-)" rating for the company. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $9.00.

Insider Buying and Selling at Oncology Institute

In other Oncology Institute news, Director Brad Hively sold 298,853 shares of the firm's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the transaction, the director owned 411,976 shares of the company's stock, valued at approximately $2,681,963.76. This trade represents a 42.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett acquired 12,000 shares of the firm's stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $6.54 per share, with a total value of $78,480.00. Following the completion of the transaction, the insider directly owned 10,660,858 shares in the company, valued at $69,722,011.32. This trade represents a 0.11% increase in their position. The disclosure for this purchase is available in the SEC filing. 4.40% of the stock is currently owned by insiders.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.